DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Jetstar to Charge for Overhead Cabin Bags From February 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
GAITHERSBURG, Md., March 20, 2018 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended December 31, 2017 before the market open and host a conference call on Thursday, March 29.
| Conference Call Details | |||
| Date: | Thursday, March 29 | ||
| Time: | 8:30am Eastern Time | ||
| Domestic: | 866-548-4713 | ||
| International: | 323-794-2093 | ||
| Conference ID: | 6280732 | ||
| Webcast: | http://public.viavid.com/index.php?id=128569 | ||
| Replays, Available through April 12th: | |||
| Domestic: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Replay PIN: | 6280732 | ||
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
[email protected]
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
[email protected]
